The Small Molecule Screening Facility runs a multiplex format cell viability assay that simultaneously reports multiple determinants of cell viability in over 18 cancer cell lines.
The Small Molecule Screening Facility runs fully quantitative wound healing and chamber migration assays in highly migratory metastatic cancer cell lines.
The Small Molecule Screening Facility has optimized Caspase 3,7,8 and 9 assays in a high throughput multiplex format. In addition assays for DNA damage and mitochondrial activity are also available.
The Small Molecule Screening Facility has assays available to simultaneously determine the total level of AKT, and phosphorylated AKT in cells treated with small molecules.
The Small Molecule Screening Facility has optimized the conditions for the TOPFLASH assay to assess the effects of small molecules on wnt/beta-catenin signaling. Other pathway specific assays are in development.
The Small Molecule Screening Facility has optimized an in vitro assay to determine levels of HDAC inhibition by small molecules. In addition, a high-throughput quantitative western blot is available to simultaneously determine the levels of acetylated histone H3 and histone H4.
In Vitro Tubulin Polymerization assays are available at the Small Molecule Screening Facility to determine the effects of small molecules on stabilization and destabilization.
The Small Molecule Screening Facility has optimized assays to determine the inhibition of protein phosphatase 1A (PP1A) and protein phosphatase 2A (PP2A) by small drug-like molecules.
The hollow fiber assay is used successfully as a routine in vivo screening model to quantitatively define anticancer activity by the National Cancer Institute. The Small Molecule Screening Facility has optimized the preparation of hollow fibers for implant into mice, and the analysis of the hollow fibers after the treatment period and removal from mice.
The Small Molecule Screening Facility has optimized the conditions to perform 48-well and 96-well western blots. Using the Odyssey imager, multiple protein bands can be visualized simultaneously and the results can be accurately quantified.
The Small Molecule Screening Facility has several assays available to assess whether or not compounds are acting as immunosuppressants in cancer cells.
The Small Molecule Screening Facility is adapting our DNA damage assays to identify compounds that act as topoisomerase inhibitors
Using our liquid handlers, plate washer, and sensitive plate readers, the Small Molecule Screening Facility can rapidly perform robust ELISAs.
The Small Molecule Screening Facility is staffed with very experienced assay developers. Please let us know if we can help you tailor our services to meet your project needs, or develop new services to assist you.